Crohn Disease

Immunology
30
Pipeline Programs
23
Companies
39
Clinical Trials
4 recruiting
3
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
1
12
0
8
5
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
3100%
+ 39 programs with unclassified modality

On Market (3)

Approved therapies currently available

UP
CIMZIAApproved
certolizumab pegol
UCB Pharma
Tumor Necrosis Factor Blocker [EPC]injection2008
AbbVie
HUMIRAApproved
adalimumab
AbbVie
2002
U
LEUKINEApproved
sargramostim
Unknown Company
Leukocyte Growth Factor [EPC]intravenous1991

Competitive Landscape

21 companies ranked by most advanced pipeline stage

AbbVie
AbbVieNORTH CHICAGO, IL
5 programs
1
1
Adalimumab InjectionPhase 41 trial
risankizumab IVPhase 2
MREN/A1 trial
MedicWiseN/A1 trial
Personalising Anti-TNF Therapy in Crohns Disease (PANTS)N/A
Active Trials
NCT05420233Recruiting600Est. Jul 2030
NCT06742385Recruiting290Est. Sep 2028
NCT03220841Unknown78Est. Sep 2021
UP
UCB PharmaBelgium - Brussels
3 programs
3
1
Certolizumab pegolPhase 31 trial
CimziaPhase 31 trial
certolizumab pegolPhase 31 trial
Active Trials
NCT00354367Withdrawn0
NCT00552344Completed403Est. Dec 2014
NCT00552058Completed439Est. Nov 2009
Celltrion
CelltrionKorea - Incheon
2 programs
1
Infliximab CT-P13Phase 41 trial
Ustekinumab 45 mgN/A1 trial
Active Trials
NCT06997055Recruiting225Est. Dec 2027
NCT05072782UnknownEst. Jun 2024
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
6 programs
5
1
BI 695501Phase 31 trial
BI 706321Phase 21 trial
Risankizumab 600 mg IVPhase 21 trial
SpesolimabPhase 2Monoclonal Antibody1 trial
SpesolimabPhase 2Monoclonal Antibody1 trial
+1 more programs
Active Trials
NCT04978493Terminated49Est. Aug 2024
NCT02513459Completed65Est. Jun 2019
NCT03752970Completed27Est. Jul 2022
+3 more trials
Sanofi
SanofiPARIS, France
2 programs
2
SargramostimPhase 31 trial
SargramostimPhase 31 trial
Active Trials
NCT00206713Terminated264Est. Oct 2006
NCT00295165Terminated33Est. Oct 2006
AB
AP BiosciencesTaiwan - Taipei
1 program
1
AZA capsulesPhase 31 trial
Active Trials
NCT05040464RecruitingEst. May 2027
Abbott
AbbottABBOTT PARK, IL
1 program
1
AdalimumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT01629628Unknown100Est. Jul 2016
Takeda
TakedaTOKYO, Japan
5 programs
1
TAK-018Phase 21 trial
ENTYVIO in Bio-naive Patients With Moderate/Severe Crohn's Disease (CD) in Daily PracticeN/A1 trial
Health-Related Quality of Life in Crohn's Disease Participants With Complex Perianal Fistula Before N/A1 trial
Paricipant Preferences in the Treatment of Inflammatory Bowel Disease (IBD) in EuropeN/A1 trial
prospective follow-up with videocapsuleN/A1 trial
Active Trials
NCT04349449Withdrawn0Est. Nov 2022
NCT04102163Terminated19Est. May 2021
NCT04597905Completed686Est. Jan 2021
+2 more trials
M&
Merck & Co.RAHWAY, NJ
4 programs
1
PRA023 IVPhase 21 trial
EndoscopyN/A1 trial
Personalising Anti-TNF Therapy in Crohns Disease (PANTS)N/A
Physician standard-of-careN/A1 trial
Active Trials
NCT01473927Completed136Est. Jun 2013
NCT01218360Completed71Est. Jan 2015
NCT05013905Completed55Est. May 2025
Qu Biologics
Qu BiologicsBC - Burnaby
1 program
1
QBECO-SSIPhase 21 trial
Active Trials
NCT03472690TerminatedEst. Feb 2021
Teva
TevaIsrael - Petach Tikva
1 program
1
TEV-48574Phase 21 trial
Active Trials
NCT05499130Completed290Est. Nov 2024
Ventyx Biosciences
Ventyx BiosciencesSAN DIEGO, CA
1 program
1
VTX958Phase 21 trial
Active Trials
NCT05688852TerminatedEst. Dec 2024
Ferring Pharmaceuticals
Ferring PharmaceuticalsArgentina - Buenos Aires
1 program
1
semapimodPhase 21 trial
Active Trials
NCT00038766Terminated33Est. Jun 2003
SetPoint Medical
SetPoint MedicalCA - Valencia
1 program
1
Cyberonics VNSPhase 1/21 trial
Active Trials
NCT02951650Unknown15Est. Aug 2018
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
AZD7798Phase 11 trial
Active Trials
NCT06432764Active Not Recruiting9Est. Apr 2026
Direct Biologics
Direct BiologicsTX - Austin
1 program
1
ExoFloPhase 11 trial
Active Trials
NCT05130983TerminatedEst. Dec 2024
MediBeacon
MediBeaconGermany - Mannheim
1 program
1
Lactulose/Rhamnose solutionPhase 11 trial
Active Trials
NCT03962998Completed22Est. Oct 2021
Avalo Therapeutics
1 program
1
MDGN-002Phase 11 trial
Active Trials
NCT03169894TerminatedEst. Oct 2021
Pfizer
PfizerNEW YORK, NY
2 programs
LYFE MD appN/A1 trial
Personalising Anti-TNF Therapy in Crohns Disease (PANTS)N/A1 trial
Active Trials
NCT04653259Unknown44Est. Oct 2022
NCT03088449Unknown1,750Est. Jul 2019
JAMP Pharma
JAMP PharmaQC - Boucherville
1 program
AVT02N/A1 trial
Active Trials
NCT05913817Completed324Est. Aug 2025
Plus Therapeutics
1 program
celluloseN/A1 trial
Active Trials
NCT04370535UnknownEst. May 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
CelltrionInfliximab CT-P13
AbbVieAdalimumab Injection
AP BiosciencesAZA capsules
Boehringer IngelheimBI 695501
AbbottAdalimumab
UCB PharmaCimzia
UCB Pharmacertolizumab pegol
UCB PharmaCertolizumab pegol
SanofiSargramostim
SanofiSargramostim
Ventyx BiosciencesVTX958
TevaTEV-48574
Boehringer IngelheimBI 706321
Merck & Co.PRA023 IV
TakedaTAK-018

Showing 15 of 39 trials with date data

Clinical Trials (39)

Total enrollment: 6,401 patients across 39 trials

NCT05072782CelltrionInfliximab CT-P13

Management of Moderate POstoperative Recurrence in Crohn's Disease: a randoMizEd contROLled Trial of Therapeutic Escalation, the POMEROL Trial. (POMEROL)

Start: Dec 2021Est. completion: Jun 2024
Phase 4Unknown
NCT03220841AbbVieAdalimumab Injection

Stricture Definition and Treatment (STRIDENT) Drug Therapy Study

Start: Oct 2017Est. completion: Sep 202178 patients
Phase 4Unknown
NCT05040464AP BiosciencesAZA capsules

Comparison of Azathioprine to Methotrexate in Combination Therapy With Adalimumab in Crohn's Disease: an Open-label Randomized Controlled Trial

Start: Aug 2021Est. completion: May 2027
Phase 3Recruiting
NCT02871635Boehringer IngelheimBI 695501

BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity

Start: Sep 2016Est. completion: May 2019147 patients
Phase 3Completed
NCT01629628AbbottAdalimumab

Adalimumab for the Management of Post-operative Crohn's Disease (CD)

Start: Jul 2012Est. completion: Jul 2016100 patients
Phase 3Unknown
NCT00552344UCB PharmaCimzia

A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease

Start: May 2008Est. completion: Dec 2014403 patients
Phase 3Completed
NCT00552058UCB Pharmacertolizumab pegol

Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease

Start: Mar 2008Est. completion: Nov 2009439 patients
Phase 3Completed
NCT00354367UCB PharmaCertolizumab pegol

Evaluate Efficacy of Certolizumab in Crohn's Patients With Draining Fistulas

Start: Jan 20070
Phase 3Withdrawn
NCT00295165SanofiSargramostim

Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease

Start: Jan 2006Est. completion: Oct 200633 patients
Phase 3Terminated
NCT00206713SanofiSargramostim

Efficacy Study of Sargramostim in the Retreatment of Patients Who Have Crohn's Disease Who Have Previously Responded to Treatment With Sargramostim

Start: Jul 2004Est. completion: Oct 2006264 patients
Phase 3Terminated
NCT05688852Ventyx BiosciencesVTX958

VTX958 for the Treatment of Moderately to Severely Active Crohn's Disease

Start: Jan 2023Est. completion: Dec 2024
Phase 2Terminated
NCT05499130TevaTEV-48574

A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease

Start: Sep 2022Est. completion: Nov 2024290 patients
Phase 2Completed
NCT04978493Boehringer IngelheimBI 706321

A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease

Start: Dec 2021Est. completion: Aug 202449 patients
Phase 2Terminated
NCT05013905Merck & Co.PRA023 IV

A Phase 2a Safety and Efficacy Open-Label Study of PRA023 in Subjects With Moderately to Severely Active Crohn's Disease

Start: Jul 2021Est. completion: May 202555 patients
Phase 2Completed
NCT03943446TakedaTAK-018

A Study of TAK-018 in Preventing the Recurrence of Crohn's Disease After Surgery

Start: Aug 2020Est. completion: Aug 202234 patients
Phase 2Terminated
NCT04362254Boehringer IngelheimSpesolimab

A Study to Test Long-term Treatment With Spesolimab in Patients With Fistulising Crohn's Disease Who Took Part in Previous Trials

Start: May 2020Est. completion: Sep 202212 patients
Phase 2Terminated
NCT03752970Boehringer IngelheimSpesolimab

A Study Testing How BI 655130 Works in Patients With Fistulizing Crohn's Disease

Start: Feb 2019Est. completion: Jul 202227 patients
Phase 2Completed
NCT03472690Qu BiologicsQBECO-SSI

QBECO SSI for Clinical and Endoscopic Remission in Moderate to Severe Crohn's Disease

Start: Jun 2018Est. completion: Feb 2021
Phase 2Terminated
NCT02513459Boehringer IngelheimRisankizumab 600 mg IV

A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease

Start: Sep 2015Est. completion: Jun 201965 patients
Phase 2Completed
NCT02031276Boehringer Ingelheimrisankizumab IV

Efficacy, Safety and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Patients With Active, Moderate-to-severe Crohn's Disease.

Start: Feb 2014Est. completion: Nov 2016121 patients
Phase 2Completed
NCT00038766Ferring Pharmaceuticalssemapimod

CNI-1493 for Treatment of Moderate to Severe Crohn's Disease

Start: Jun 2002Est. completion: Jun 200333 patients
Phase 2Terminated
NCT02951650SetPoint MedicalCyberonics VNS

Long Term Observational Study of a Vagal Nerve Stimulation Device in Crohn's Disease

Start: Jan 2015Est. completion: Aug 201815 patients
Phase 1/2Unknown
NCT06432764AstraZenecaAZD7798

Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Patients With Crohn's Disease.

Start: Oct 2024Est. completion: Apr 20269 patients
Phase 1Active Not Recruiting
NCT05130983Direct BiologicsExoFlo

Study of ExoFlo for the Treatment of Medically Refractory Crohn's Disease

Start: Jan 2023Est. completion: Dec 2024
Phase 1Terminated
NCT03962998MediBeaconLactulose/Rhamnose solution

Oral Administration of MB-102 Versus Dual Sugar Testing for Gut Permeability

Start: Oct 2019Est. completion: Oct 202122 patients
Phase 1Completed
NCT03169894Avalo TherapeuticsMDGN-002

Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis

Start: Jul 2017Est. completion: Oct 2021
Phase 1Terminated
NCT06742385AbbVieMedicWise

Evaluation of a Remote Monitoring Application in the Follow-up of Patients With Active Inflammatory Bowel Diseases

Start: Sep 2025Est. completion: Sep 2028290 patients
N/ARecruiting
NCT06997055CelltrionUstekinumab 45 mg

ROLL'YN-UST: an Observational Study in Patients Treated by Steqeyma®, an Ustekinumab Biosimilar

Start: Mar 2025Est. completion: Dec 2027225 patients
N/ARecruiting
NCT05913817JAMP PharmaAVT02

The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.

Start: Jan 2023Est. completion: Aug 2025324 patients
N/ACompleted
NCT05420233AbbVieMRE

The CROCO Study: CROhn's Disease COhort Study

Start: Aug 2021Est. completion: Jul 2030600 patients
N/ARecruiting
NCT04653259PfizerLYFE MD app

Digital Nutrition Therapy for Patients With IBD

Start: May 2021Est. completion: Oct 202244 patients
N/AUnknown
NCT04102163TakedaHealth-Related Quality of Life in Crohn's Disease Participants With Complex Perianal Fistula Before

Health-Related Quality of Life in Crohn's Disease Participants With Complex Perianal Fistula Before and After Treatment

Start: Jan 2021Est. completion: May 202119 patients
N/ATerminated
NCT04597905TakedaParicipant Preferences in the Treatment of Inflammatory Bowel Disease (IBD) in Europe

Paricipant Preferences in the Treatment of Inflammatory Bowel Disease (IBD) in Europe

Start: Oct 2020Est. completion: Jan 2021686 patients
N/ACompleted
NCT04349449TakedaENTYVIO in Bio-naive Patients With Moderate/Severe Crohn's Disease (CD) in Daily Practice

ENTYVIO in Bio-naive Patients With Moderate/Severe Crohn's Disease (CD) in Daily Practice

Start: Sep 2020Est. completion: Nov 20220
N/AWithdrawn
NCT03889613Takedaprospective follow-up with videocapsule

Pillcam Crohn's Capsule for Monitoring of Panenteric Mucosal Healing in Crohn's Disease Patients With Vedolizumab

Start: Apr 2019Est. completion: Nov 202460 patients
N/AUnknown
NCT04370535Plus Therapeuticscellulose

PMA-Zeolite-Clinoptilolite Effects in Crohn Disease

Start: Oct 2018Est. completion: May 2020
N/AUnknown
NCT03088449PfizerPersonalising Anti-TNF Therapy in Crohns Disease (PANTS)

Personalising Anti-TNF Therapy in Crohns Disease (PANTS)

Start: Mar 2013Est. completion: Jul 20191,750 patients
N/AUnknown
NCT01218360Merck & Co.Physician standard-of-care

Observational Study of Disease Severity in Participants Diagnosed With Crohn's Disease and Long Term Impact of Treatment Strategies in Participants With Moderate to Severe Crohn's Disease (Protocol P06484)

Start: Nov 2011Est. completion: Jan 201571 patients
N/ACompleted
NCT01473927Merck & Co.Endoscopy

Significance of Ficolin 2 in the Determination of Serological Activity in Chronic Inflammatory Bowel Disease

Start: Oct 2011Est. completion: Jun 2013136 patients
N/ACompleted

Related Jobs in Immunology

Regulatory Affairs Manager(Immunology), Korea

AbbVie
Seoul, Seoul
6h ago

Regional Sales Trainer - Rheumatology (Mid Atlantic/Central)

AbbVie
Remote
7h ago

Product Specialist - Immunology

Johnson & Johnson
Kibbutz Shefayim, Center District, Israel
20h ago

Senior Area Business Specialist, Immunology - Detroit, MI - Johnson & Johnson Innovative Medicine

Johnson & Johnson
Detroit, Michigan, United States
20h ago

Senior Medical Science Liaison, Dermatology - Indianapolis

Johnson & Johnson
Indianapolis, Indiana, United States
20h ago
$137K - $236K/yr

Field Reimbursement Manager - Rheumatology - Seattle, WA (North)

Johnson & Johnson
Seattle, Washington, United States of America
20h ago
$100K - $175K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

8 late-stage (Phase 3) programs — potential near-term approvals
4 actively recruiting trials targeting 6,401 patients
23 companies competing in this space

Related Indications

Rheumatoid Arthritis(475)Psoriasis(206)Ulcerative Colitis(151)Atopic Dermatitis(144)Crohn's Disease(140)Systemic Lupus Erythematosus(85)Arthritis, Rheumatoid(61)Plaque Psoriasis(53)Ankylosing Spondylitis(33)Chronic Plaque Psoriasis(26)